Octreotide acetate
mRNA synthesis
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
SYBR Safe DNA Gel Stain
Safe and sensitive stain for visualization of DNA or RNA in agarose or acrylamide gels.
Inhibitor Cocktails
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
Octreotide acetate(Sandostatin)是自身生长抑素的八肽同族物,可抑制胰岛素和胰高血糖素分泌.该物质可通过调控脑下垂体生长激素分泌,减少肝脏中IGF-1和IGF-2生成.[1]
胰岛素样生长因子IGF-1和IGF-2,是一种内源性的多肽激素,可有效刺激细胞增殖,正被研究用于前列腺癌的临床靶点.
Octreotide acetate可降低尿酸的尿排泄和胰高血糖素及胰岛素的血浆浓度.Octreotide acetate可降低钠和氯的尿排泄,并不显著影响肌酐清除率,而血液中的乳酸\丙酮酸和血浆中的环AMP并未改变.[1]
参考文献：
[1] Tetsuya yamamoto, Yuji moriwaki et al. Effect of Octreotide acetate on the Plasma Concentration and Urinary Excretion of Uridine and Purine Bases. Endocrine Journal 2002, 49(2),139-144.
| Physical Appearance | A solid |
| Storage | Store at -20°C |
| M.Wt | 1079.29 |
| Cas No. | 79517-01-4 |
| Formula | C51H70N10O12S2 |
| Synonyms | SMS 201995; Sandostatin |
| Solubility | ≥53.96 mg/mL in DMSO; ≥10.04 mg/mL in EtOH; ≥28.85 mg/mL in H2O |
| Chemical Name | (4S,7S,10S,13R,16S,19R)-13-((1H-indol-3-yl)methyl)-19-((R)-2-amino-3-phenylpropanamido)-10-(4-aminobutyl)-16-benzyl-N-((2R,3R)-1,3-dihydroxybutan-2-yl)-7-((R)-1-hydroxyethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide |
| SDF | Download SDF |
| Canonical SMILES | O=C(N[C@H](CC1=CNC2=CC=CC=C12)C3=O)[C@@H](NC([C@@H](NC([C@H](N)CC4=CC=CC=C4)=O)CSSC[C@H](C(N[C@@H]([C@H](O)C)CO)=O)NC([C@](NC([C@H](CCCCN)N3)=O)([H])[C@H](O)C)=O)=O)CC5=CC=CC=C5.CC(O)=ON)C(=O)NC(CO)C(C)O)O.CC(=O)O |
| 运输条件 | 蓝冰运输或根据您的需求运输。 |
| 一般建议 | 不同厂家不同批次产品溶解度各有差异，仅做参考。若实验所需浓度过大至产品溶解极限，请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存，请尽快用完。 |
| 细胞实验 [1]: | |
|
细胞系 |
人类HUV-EC-C内皮细胞 |
|
制备方法 |
该化合物在DMSO中的溶解度大于10 mM。若配制更高浓度的溶液，一般步骤如下：请将试管置于37℃加热10分钟和/或将其置于超声波浴中震荡一段时间。原液于-20℃可放置数月。 |
|
反应条件 |
1 μM, 72 hours |
|
实验结果 |
与对照组培养物相比，1 nM Octreotide将细胞增殖减少45.8％，从9.7×103减少到4.4×103个细胞/孔。为了评估介质补充剂对HUV-EC-C细胞生长抑制的影响，针对培养基中的ECGF和肝素的分级浓度测试octreotide的效果。总之，与基线条件相比，这些变化没有显著影响octreotide的生长抑制活性。 |
| 动物实验 [2]: | |
|
动物模型 |
雄性Sprague-Dawley大鼠 |
|
给药剂量 |
皮下注射， 1 µg/kg、10 µg/kg和200 µg/kg |
|
实验结果 |
使用1 μg/kg octreotide处理后，NREMS和SWA均正常，但是，REMS在光照期显著增强。注射后2-3小时REMS开始增加，并在之后一天的时间中持续，尽管当考虑个体时间时它们的增加非常少。10 μg/kg octreotide注射后1小时内NREMS被显著抑制。计算12 h光照期，NREMS或SWA在基线和octreotide之间没有差异。 |
|
注意事项 |
请于室内测试所有化合物的溶解度。虽然化合物的实际溶解度可能与其理论值略有不同，但仍处于实验系统误差的允许范围内。 |
|
References: [1] Danesi R, Agen C, Benelli U, et al. Inhibition of experimental angiogenesis by the somatostatin analogue octreotide acetate (SMS 201-995). Clinical Cancer Research, 1997, 3(2): 265-272. [2] Beranek L, Obal Jr F, Taishi P, et al. Changes in rat sleep after single and repeated injections of the long-acting somatostatin analog octreotide. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 1997, 273(4): R1484-R1491. |
|
质量控制和MSDS
- 批次:
化学结构
